Avant Technologies and Austrianova Sign Joint Venture, Licensing Agreement to Advance Klotho-Based Therapies
Avant Technologies (OTCQB: AVAI) and Austrianova have formed a joint venture called Klothonova, Inc. to develop cell-based therapies using encapsulated Klotho-producing cells. The 50/50 partnership combines Austrianova's proprietary cell-encapsulation technology and expertise with Avant's capital and resources.
The venture aims to develop treatments for Alzheimer's disease, heart disease, cancer, kidney disease, and age-related conditions. Austrianova brings significant expertise backed by over 50 peer-reviewed publications and global partnerships, while focusing on the therapeutic properties of Klotho, an 'anti-aging' protein discovered in 1997 that plays a crucial role in modulating aging and various physiological functions.
Avant Technologies (OTCQB: AVAI) e Austrianova hanno creato una joint venture chiamata Klothonova, Inc. per sviluppare terapie cellulari basate su cellule produttrici di Klotho incapsulate. La partnership 50/50 unisce la tecnologia proprietaria di incapsulamento cellulare di Austrianova e la sua esperienza con il capitale e le risorse di Avant.
L'iniziativa mira a sviluppare trattamenti per malattia di Alzheimer, malattie cardiache, cancro, malattie renali e condizioni legate all'invecchiamento. Austrianova apporta una notevole esperienza supportata da oltre 50 pubblicazioni sottoposte a revisione paritaria e collaborazioni a livello globale, concentrandosi sui benefici terapeutici della Klotho, una proteina “anti-età” scoperta nel 1997 che svolge un ruolo cruciale nel modulare l'invecchiamento e varie funzioni fisiologhe.
Avant Technologies (OTCQB: AVAI) y Austrianova han formado una joint venture llamada Klothonova, Inc. para desarrollar terapias basadas en células utilizando células productoras de Klotho encapsuladas. La asociación 50/50 combina la tecnología y experiencia propietarias de encapsulación celular de Austrianova con el capital y los recursos de Avant.
La empresa conjunta tiene como objetivo desarrollar tratamientos para enfermedad de Alzheimer, enfermedad cardíaca, cáncer, enfermedad renal y condiciones relacionadas con el envejecimiento. Austrianova aporta una experiencia significativa respaldada por más de 50 trabajos revisados por pares y asociaciones globales, centrándose en las propiedades terapéuticas de la Klotho, una proteína 'anti-envejecimiento' descubierta en 1997 que desempeña un papel crucial en la modulación del envejecimiento y diversas funciones fisiológicas.
Avant Technologies (OTCQB: AVAI) 와 Austrianova는 encapsulated Klotho-producing cells를 이용한 세포 기반 치료를 개발하기 위해 Klothonova, Inc.라는 합작회사를 설립했습니다. 50/50의 파트너십은 Austrianova의 독점적 세포 캡슐화 기술과 전문 지식과 Avant의 자본 및 자원을 결합합니다.
이 벤처의 목표는 알츠하이머 병, 심장병, 암, 신장 질환, 노화 관련 질환에 대한 치료법 개발입니다. Austrianova는 50편 이상의 동료 평가 논문과 글로벌 파트너십으로 뒷받침되는 상당한 전문 지식을 제공하며, 노화 억제 및 다양한 생리 기능 조절에 중요한 역할을 하는 1997년에 발견된 'anti-aging' 단백질인 클로토(Klotho)의 치료적 특성에 집중합니다.
Avant Technologies (OTCQB: AVAI) et Austrianova ont formé une coentreprise nommée Klothonova, Inc. pour développer des thérapies cellulaires utilisant des cellules productrices de Klotho encapsulées. Le partenariat 50/50 combine la technologie d'encapsulation cellulaire propriétaire d'Austrianova et son expertise avec le capital et les ressources d'Avant.
La société vise à développer des traitements pour la maladie d'Alzheimer, les maladies cardiaques, le cancer, les maladies rénales et les conditions liées au vieillissement. Austrianova apporte une expertise significative soutenue par plus de 50 publications évaluées par des pairs et des partenariats mondiaux, tout en se concentrant sur les propriétés thérapeutiques du Klotho, une protéine « anti-âge » découverte en 1997 et jouant un rôle crucial dans la modulation du vieillissement et diverses fonctions physiologiques.
Avant Technologies (OTCQB: AVAI) und Austrianova haben eine Joint Venture namens Klothonova, Inc. gegründet, um zellbasierte Therapien unter Verwendung encapsulierter Klotho-produzierender Zellen zu entwickeln. Die 50/50-Partnerschaft verbindet Austrianovas proprietäre Zellencapsulation-Technologie und Fachwissen mit Avants Kapital und Ressourcen.
Das Vorhaben zielt darauf ab, Behandlungen für Alzheimer-Krankheit, Herzkrankheiten, Krebs, Nierenerkrankungen und altersbedingte Bedingungen zu entwickeln. Austrianova bringt signifikante Fachkompetenz mit, unterstützt durch über 50 begutachtete Veröffentlichungen und globale Partnerschaften, während der Fokus auf den therapeutischen Eigenschaften von Klotho liegt, einem 1997 entdeckten ‚Anti-Aging‘-Protein, das eine entscheidende Rolle bei der Modulation des Alterungsprozesses und verschiedener physiologischer Funktionen spielt.
Avant Technologies (OTCQB: AVAI) وAustrianova أنشأتا مشروعاً مشتركاً يُدعى Klothonova, Inc. لتطوير علاجات خلوية باستخدام خلايا منتجة لـ Klotho مغلَّفة. الشراكة 50/50 تجمع بين تقنية أغشنة الخلايا المملوكة لـ Austrianova وخبراتها مع رأس مال Avant ومواردها.
يهدف المشروع إلى تطوير علاجات لـمرض الزهايمر، أمراض القلب، السرطان، أمراض الكلى، والاضطرابات المرتبطة بالشيخوخة. تقدم Austrianova خبرة كبيرة مدعومة بأكثر من 50 منشوراً مُراجَعاً من قِبل النظراء وشراكات عالمية، مع تركيز على الخصائص العلاجية لـ Klotho، البروتين «مضاد للشيخوخة» الذي كُشف في 1997 ويلعب دوراً حاسماً في تعديل الشيخوخة ووظائف فسيولوجية مختلفة.
Avant Technologies (OTCQB: AVAI) 与 Austrianova 已成立合资企业 Klothonova, Inc.，以开发利用包裹的Klotho-生成细胞的细胞治疗。该合资企业采取50/50的伙伴关系，将Austrianova的专有细胞封装技术和专业知识与Avant的资本与资源结合起来。
该企业旨在开发治疗阿尔茨海默病、心脏病、癌症、肾病及与年龄相关的疾病等疾病的治疗方法。Austrianova凭借超过50篇同行评审出版物与全球伙伴关系提供重要专业知识，同时聚焦于Klotho的治疗特性——一种在1997年发现的“抗衰老”蛋白，在调节衰老及多种生理功能方面发挥着关键作用。
- Formation of a strategic 50/50 joint venture with an established biotech leader
- Access to Austrianova's proprietary cell-encapsulation technology and extensive research portfolio
- Exclusive license to develop treatments for multiple major diseases and conditions
- Targeting large market opportunities in Alzheimer's, cancer, heart disease, and anti-aging therapies
- Early-stage venture with no immediate revenue generation potential
- Development and commercialization timeline uncertainties
- Significant capital requirements for multiple treatment programs
- Regulatory approval risks for novel cell-based therapies
Under the terms of the agreement, Klothonova will leverage Austrianova's proprietary cellencapsulation technology to develop and commercialize treatments targeting Alzheimer's disease, heart disease, cancer, kidney disease, other age-related conditions, and longevity promotion. Austrianova, renowned for its expertise in cell biology, GMP-grade cell products, and encapsulation technologies - backed by over 50 peer-reviewed publications and partnerships with global pharmaceutical and biotech companies - will contribute its intellectual property and 'know-how' to the venture. Avant will provide capital, along with additional resources, to support Klothonova's formation and operations.
Klothonova will operate as a 50/50 joint venture, with ownership equally split between Avant and Austrianova. The company will be focusing on developing innovative treatments through the over expression of the Klotho protein, encapsulated using Austrianova's cutting-edge technology. This exclusive license will enable Klothonova to address critical medical needs and explore longevity-enhancing solutions across global markets.
"We are thrilled to partner with Austrianova, whose world-class expertise in cell encapsulation and GMP manufacturing complements our vision for advancing transformative healthcare solutions," said Chris Winter, Chief Executive Officer (CEO) at Avant Technologies.
"Klothonova represents a significant step toward addressing some of the most pressing medical challenges of our time."
Austrianova's CEO, Brian Salmons, added, "This joint venture with Avant Technologies allows us to combine our proprietary technologies with Avant's resources to accelerate the development of Klotho-based therapies. We are excited about the potential to improve patient outcomes and promote healthier, longer lives."
Klotho is regarded as an 'anti-aging' protein, known for its crucial role in modulating aging and supporting diverse physiological functions. Discovered in 1997, it is primarily produced in the kidneys and brain and has been linked to improved cognitive function, cardiovascular health, and kidney function, while also showing potential in combating age-related diseases such as Alzheimer's, cancer, and heart disease. By leveraging Klotho's therapeutic properties through advanced cell encapsulation technology, Klothonova is poised to become a leader in the biotech industry, with a mission to develop and commercialize innovative treatments that enhance quality of life and promote longevity
Klothonova will prioritize the development of treatments for major indications, with each program independently managed to ensure focused progress. This strategic collaboration positions Klothonova to lead in the rapidly evolving field of cell-based therapeutics.
About Avant Technologies Inc.
Avant Technologies Inc. is an emerging
About Austrianova (SGAustria Pte. Ltd.)
Austrianova, based in
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies Inc.
info@avanttechnologies.com
Logo: https://mma.prnewswire.com/media/2370694/5517509/Avant_Technologies.jpg
View original content:https://www.prnewswire.com/news-releases/avant-technologies-and-austrianova-sign-joint-venture-licensing-agreement-to-advance-klotho-based-therapies-302560453.html
SOURCE Avant Technologies Inc.
FAQ
What is the new joint venture between Avant Technologies (OTCQB: AVAI) and Austrianova?
What diseases will Klothonova target with its Klotho-based therapies?
What is Klotho and why is it important for Avant Technologies' new venture?
What does Austrianova bring to the Klothonova joint venture?
What is Avant Technologies' contribution to the Klothonova partnership?
